Αποτελέσματα Αναζήτησης
14 Μαρ 2023 · At the Conference on Retroviruses and Opportunistic Infections (CROI 2023) in February, many researchers presented studies looking at new drugs being tested for use as treatment, pre-exposure prophylaxis (PrEP), and post-exposure prophylaxis (PEP). Here are some highlights.
21 Ιουν 2023 · Data to inform the switch from a ritonavir-boosted protease inhibitor (PI) to dolutegravir in patients living with human immunodeficiency virus (HIV) infection who do not have genotype...
23 Δεκ 2021 · Apretude, a new drug approved by the FDA this week, is an injection that has proven to be significantly more effective at reducing the risk of sexually-acquired HIV.
In this review, we provide an overview on currently available anti-HIV drugs and the latest developments in antiretroviral therapy, focused on new antiretroviral agents acting on known and unexploited antiviral targets, prevention therapies aimed to improve available drug combinations, and research on new long-acting therapies, particularly ...
4 Ιαν 2023 · Sunlenca is the first of a new class of drugs called capsid inhibitors to be FDA-approved for treating HIV-1. Sunlenca works by blocking the HIV-1 virus’ protein shell (the capsid), thereby interfering with multiple essential steps of the viral lifecycle.
18 Νοε 2021 · Thousands of people with HIV will now be offered a new long-acting injection to manage their condition if they would prefer to stop taking daily pills. Charities have welcomed the approval of...
10 Ιαν 2023 · The FDA has approved Gilead Science’s first-in-class capsid inhibitor lenacapavir, providing a new treatment option for people with multidrug-resistant HIV. Many patients already respond well...
